We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BIO Stock Might Rise Following the Offer to Acquire Stilla
Read MoreHide Full Article
Bio-Rad Laboratories, Inc. (BIO - Free Report) recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions complement Bio-Rad’s digital PCR portfolio. The acquisition should further expand Bio-Rad’s business into applied research and clinical diagnostics, where customers expect a higher degree of automation and throughput capabilities.
The acquisition is subject to consultation with relevant employee representatives, regulatory approvals and other customary closing conditions. The acquisition is expected to be closed by the end of the third quarter of 2025.
BIO Stock Likely Trend Following the News
Since the announcement, BIO stock has lost 9.5% to $277.16 last Friday.
The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical diagnostic applications, both directly and through various partnerships. In 2024, Bio-Rad was involved in various collaborations, including an additional equity investment in OncoCyte Corporation and association with Allegheny Health Network. Accordingly, we expect the latest acquisition offer to bolster investor confidence and bring back the upward momentum in BIO's share price in the coming days.
Bio-Rad has a market capitalization of $7.94 billion. The Zacks Consensus Estimate for fiscal 2025 earnings indicates a 12.2% year-over-year increase on a 3.4% revenue improvement.
Importance of Bio-Rad’s Acquisition of Stilla
Stilla develops and markets next-generation digital PCR instruments, consumables and assays. Its Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications, including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.
The Stilla platform would allow Bio-Rad to serve the full range of digital PCR applications and help meet the evolving needs of customers in genomics research and applied science. In lieu of this, Bio-Rad plans to launch its QX Continuum system.
Image Source: Zacks Investment Research
Industry Prospects Favor Bio-Rad
Per a report by Fortune Market Insights, the global digital PCR market was valued at $584.5 million in 2023 and is projected to grow to $3.68 billion by 2032, exhibiting a CAGR of 22.9% during the period. The rise in prevalence of infectious diseases, cancer, and genetic disorders, technological advancements, and the growing adoption of the technology by laboratories are some of the key factors expected to drive the market growth.
BIO’ Price Performance
In the past year, BIO’s shares have declined 18.6% against the industry’s 13.9% growth.
BIO’ Zacks Rank and Other Key Picks
The company currently carries a Zacks Rank #2 (Buy).
VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
ResMed, carrying a Zacks Rank #2 at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BIO Stock Might Rise Following the Offer to Acquire Stilla
Bio-Rad Laboratories, Inc. (BIO - Free Report) recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions complement Bio-Rad’s digital PCR portfolio. The acquisition should further expand Bio-Rad’s business into applied research and clinical diagnostics, where customers expect a higher degree of automation and throughput capabilities.
The acquisition is subject to consultation with relevant employee representatives, regulatory approvals and other customary closing conditions. The acquisition is expected to be closed by the end of the third quarter of 2025.
BIO Stock Likely Trend Following the News
Since the announcement, BIO stock has lost 9.5% to $277.16 last Friday.
The company has been gaining synergies from its digital PCR platform’s increased penetration in advanced clinical diagnostic applications, both directly and through various partnerships. In 2024, Bio-Rad was involved in various collaborations, including an additional equity investment in OncoCyte Corporation and association with Allegheny Health Network. Accordingly, we expect the latest acquisition offer to bolster investor confidence and bring back the upward momentum in BIO's share price in the coming days.
Bio-Rad has a market capitalization of $7.94 billion. The Zacks Consensus Estimate for fiscal 2025 earnings indicates a 12.2% year-over-year increase on a 3.4% revenue improvement.
Importance of Bio-Rad’s Acquisition of Stilla
Stilla develops and markets next-generation digital PCR instruments, consumables and assays. Its Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications, including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.
The Stilla platform would allow Bio-Rad to serve the full range of digital PCR applications and help meet the evolving needs of customers in genomics research and applied science. In lieu of this, Bio-Rad plans to launch its QX Continuum system.
Image Source: Zacks Investment Research
Industry Prospects Favor Bio-Rad
Per a report by Fortune Market Insights, the global digital PCR market was valued at $584.5 million in 2023 and is projected to grow to $3.68 billion by 2032, exhibiting a CAGR of 22.9% during the period. The rise in prevalence of infectious diseases, cancer, and genetic disorders, technological advancements, and the growing adoption of the technology by laboratories are some of the key factors expected to drive the market growth.
BIO’ Price Performance
In the past year, BIO’s shares have declined 18.6% against the industry’s 13.9% growth.
BIO’ Zacks Rank and Other Key Picks
The company currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , ResMed (RMD - Free Report) and Omnicell (OMCL - Free Report) .
Veracyte, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
ResMed, carrying a Zacks Rank #2 at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Omnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.